Last reviewed · How we verify
FDA Accelerated Approval Pathway
How accelerated approval works
The FDA can approve a drug for a serious condition based on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The sponsor commits to a confirmatory study (Phase 4) demonstrating actual clinical benefit. If the confirmatory trial fails, the FDA can withdraw approval. Approval is "accelerated" in that it happens before the ultimate clinical outcome (survival, hospitalisation, etc.) is measured.
When accelerated approval is used
Most accelerated approvals are in oncology, where tumour response rate is the surrogate endpoint and overall survival or progression-free survival is the confirmatory endpoint. Other examples: HIV (CD4 count / viral load), Alzheimer's (anti-amyloid antibodies on PET imaging), rare metabolic disease (biomarker normalisation). The condition has to be serious — accelerated approval is not available for routine outpatient indications.
Confirmatory trials + withdrawal
Sponsors must run post-marketing confirmatory trials. If those fail, the FDA can withdraw the accelerated approval — and has done so several times (Makena, Aduhelm partial withdrawal). The FDA Modernization Act of 2022 strengthened the FDA's authority to require confirmatory trials and accelerated their timelines.
Why it matters for sponsors
Accelerated approval can bring a drug to market 1–4 years earlier than traditional approval. That's billions of dollars in NPV terms for blockbuster candidates. But it also creates regulatory + reputational risk if the confirmatory trial fails.
FAQ
Is accelerated approval less rigorous?
The safety bar is the same; the efficacy bar is different — based on surrogate vs ultimate outcome. The trade-off: drugs can be approved + available faster, but post-marketing confirmation is essential.
What happens if the confirmatory trial fails?
The FDA can withdraw approval. Recent examples: melflufen (Pepaxto) — withdrawn 2021; pyramax (artemisinin combination) — withdrawn in some indications. Sponsors typically withdraw voluntarily to avoid regulatory action.
Which drugs got accelerated approval?
Keytruda (multiple oncology indications), lecanemab (Leqembi, Alzheimer's — surrogate: amyloid clearance), donanemab (Kisunla, similar), many CDK4/6 inhibitors in early breast cancer, many HER2 ADCs. ~85% of accelerated approvals are in oncology.